Key result
Piceatannol pretreatment suppressed isoproterenol-induced cardiac hypertrophy in vivo and in rat neonatal cardiomyocytes by reducing the interaction between GATA4 and GATA6.
Why the study?
Does piceatannol prevent cardiac hypertrophy in animal and cellular models?
Does piceatannol prevent cardiac hypertrophy in animal and cellular models?
Piceatannol attenuates cardiac hypertrophy in preclinical models by regulating GATA6 expression and binding, suggesting potential as a novel therapeutic agent.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for piceatannol in hypertrophy pending human trials.
Piceatannol is found in grapes, passion fruit, and Japanese knotweed. Piceatannol pretreatment suppresses cardiac hypertrophy induced by isoproterenol as assessed by heart weight/body weight ratio, cross-sectional area, and expression of hypertrophic markers. The anti-hypertrophic effect of piceatannol in rat neonatal cardiomyocytes is the same as that in vivo. Piceatannol inhibits lentiviral-GATA6-induced cardiomyocyte hypertrophy. Furthermore, piceatannol reduces the interaction between GATA4 and GATA6 as well as the DNA-binding activity of endogenous GATA6 in the ANP promoter. Our results suggest that piceatannol may be a novel therapeutic agent for the prevention of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Kee et al. (2014) studied Cardiac hypertrophy. Piceatannol was evaluated on Cardiac hypertrophy (assessed by heart weight/body weight ratio, cross-sectional area, and expression of hypertrophic markers). Piceatannol pretreatment suppressed isoproterenol-induced cardiac hypertrophy in vivo and in rat neonatal cardiomyocytes by reducing the interaction between GATA4 and GATA6.
Synapse has enriched 10 related papers. Consider them for comparative context: